

Article

Palladium-Catalyzed Tsuji–Trost-Type Reaction of 3-Indolylmethylacetates with O, and S Soft Nucleophiles

Antonia Iazzetti ^{1,2,*}, Antonio Arcadi ³, Marco Chiarini ⁴, Giancarlo Fabrizi ^{5,*}, Antonella Goggiamani ⁵, Federico Marrone ⁵, Andrea Serraiocco ⁵ and Roberta Zoppoli ⁵

¹ Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, L. go Francesco Vito 1, 00168 Rome, RM, Italy

² Policlinico Universitario 'A. Gemelli' Foundation-IRCCS, 00168 Rome, RM, Italy

³ Dipartimento di Scienze Fisiche e Chimiche, Università degli Studi di L'Aquila, Via Vetoio, 67100 Coppito, AQ, Italy; antonio.arcadi@univaq.it

⁴ Dipartimento di Bioscienze e Tecnologie Agro-Alimentari e Ambientali, Università di Teramo, Via R. Balzarini, 64100 Teramo, TE, Italy; mchiarini@unite.it

⁵ Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza, Università di Roma, P. le A. Moro 5, 00185 Rome, RM, Italy; antonella.goggiamani@uniroma1.it (A.G.); federico.marrone@uniroma1.it (F.M.); andrea.serraiocco@uniroma1.it (A.S.); roberta.zoppoli@uniroma1.it (R.Z.)

* Correspondence: antonia.iazzetti@unicatt.it (A.I.); giancarlo.fabrizi@uniroma1.it (G.F.)

Abstract: The chemical valorization of widespread molecules in renewable sources is a field of research widely investigated in the last decades. In this context, we envisaged that indole-3-carbinol, present in different *Cruciferae* plants, could be a readily available building block for the synthesis of various classes of indoles through a palladium-catalyzed Tsuji–Trost-type reaction with O and S soft nucleophiles. The regiochemical outcome of this high-yielding functionalization shows that the nucleophilic substitution occurs only at the benzylic position. Interestingly, with this protocol, the sulfonyl unit could be appended to the indole nucleus, providing convenient access to new classes of molecules with potential bioactivity.

Keywords: 3-carbinol; Tsuji–Trost-type reaction; O and S soft nucleophiles; renewable sources



Citation: Iazzetti, A.; Arcadi, A.; Chiarini, M.; Fabrizi, G.; Goggiamani, A.; Marrone, F.; Serraiocco, A.; Zoppoli, R. Palladium-Catalyzed Tsuji–Trost-Type Reaction of 3-Indolylmethylacetates with O, and S Soft Nucleophiles. *Molecules* **2024**, *29*, 3434. <https://doi.org/10.3390/molecules29143434>

Academic Editor: Wai Lun Man

Received: 4 July 2024

Revised: 17 July 2024

Accepted: 19 July 2024

Published: 22 July 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Nowadays, the valorization of bioactive compounds found in natural sources is gaining high interest due to the growing trend of promoting the use of renewable resources following a circular biobased approach towards natural product-based drug discovery [1]. Significant efforts have been made to establish sustainable processes in which natural scaffolds are extracted and chemically modified using efficient catalytic methods, aiming to create molecules with improved biological properties [2].

One of the most common kinds of natural products of biological relevance is represented by indole-containing alkaloids, with more than 4100 examples. A large number of them have been deeply examined for their remarkable anticancer, antibacterial, antiviral, antifungal, and antiplasmodial activities, attracting significant attention as possible leads for novel therapies [3].

In this regard, an excellent instance is represented by the indole-3-carbinol (I3C) **1** (Figure 1).

Particularly, it is a naturally occurring phytochemical found in the *Brassicaceae* species of cruciferous vegetables derived from the myrosinase-catalyzed hydrolysis of glyco Brassicacin **2** (Figure 1) [4]. I3C has been found to exhibit antioxidative, anti-inflammatory, antiatherogenic, antiviral, antithrombotic, and, most notably, anticarcinogenic activity [5–16].

Despite this broad spectrum of activities and its high therapeutic potential, many drawbacks, notably its metabolic instability, limit the I3C development in drug discovery;

therefore, structural modifications of this nucleus remain a challenging and demanding research subject [17].





Figure 1. Indole-3-carbinol (I3C) **1** and glycoibrassicin **2** structures.

Synthetic transformations for the functionalization of the indole nucleus based on indole carbinole and its derivatives are described and widely employed. Among them, two main approaches are explored:

1. in situ generation under acidic or basic reaction conditions of highly unstable and reactive transient indole methides followed by the regioselective conjugated addition of nucleophiles [18,19]. This approach has been strictly correlated to in situ aza-o-QMs generation/nucleophile Michael-type [20,21];
2. Tsuji–Trost-type reaction. Indeed, analogous to electrophilic systems of heteroaromatics with extended π conjugation featuring carboxylate and carbonate leaving groups, activated carbinols can generate π -(η^3 indolyl)–palladium electrophilic intermediates in the presence of Pd(0) in equilibrium with cationic π -(η^1 -indolyl)–palladium complexes [22].

Recently, part of our studies focused on the functionalization of indoles using activated carbinols as precursors of transient indole methides [18] or as substrates for palladium-catalyzed Tsuji–Trost-type reactions with different classes of carbon soft nucleophiles [23] and Suzuki–Miyaura cross-coupling with aryl boronic acids [24]. These synthetic approaches are summarized in Scheme 1.



Scheme 1. Our previous works on the reactivity of activated indole-3-carbinol (I3C). (a) [24] (b) [23] (c) [18].

However, since the functionalization of indole-3-carbinol with O and S soft nucleophiles was not explored, based on our background, we hypothesized that (1-substituted-indol-3-

yl)methyl acetates **3** could be readily available precursors of two classes of indole-containing derivatives: 1-substituted 3-(aryloxymethyl)-1*H*-indole **4** and 3-((arylsulfonyl)methyl)-1*H*-indole **5** (Figure 2) through palladium-catalyzed Tsuji–Trost-type reactions with phenols or aryl sulfinates as soft nucleophiles, respectively (Scheme 2).





Figure 2. Structures of 1-substituted 3-(aryloxymethyl)-1*H*-indole **4** and 3-((arylsulfonyl)methyl)-1*H*-indole **5**.



Scheme 2. Working hypothesis.

The aryloxy and arylsulfonyl groups attached to the indole scaffold appeared interesting to us allowing for structural modifications that can fine-tune pharmacological properties. This versatility is crucial for optimizing drug potency, selectivity, and pharmacokinetic properties.


To the best of our knowledge, the compounds **4** were synthesized for the first time by Yongxiang Liu from (1-tosyl-1*H*-indol-3-yl)methanol and phenols via Mitsunobu reaction with an approximate yield of 50% [25].

Hereafter we report the results of our investigation.

2. Results

The choice of (1-substituted-1*H*-indol-3-yl)methyl acetates **3** instead of (1*H*-indol-3-yl)methyl acetate as precursors for the functionalization of activated I3C with O and S soft nucleophiles is due to the low selectivity in N/O acetylation of the N-free I3C under different reaction conditions [18,23].


The (1-substituted-indol-3-yl)methyl acetates **3** were obtained with excellent overall yield from renewable sources I3C **1** according to the four-step sequence outlined in Scheme 3. Interestingly, the oxidation **1** to the corresponding 3-formylindole derivative was performed using IBX [26], a nonmetallic green oxidant with excellent recyclability [27]. Moreover, the reduction and acetylation reactions did not require any purification.



Scheme 3. Synthesis of (1-substituted-indol-3-yl)methyl acetates **3**.

The reaction of **3a–c** with 4-methoxyphenol **6a** was initially explored. Part of our optimization study using different ligands, solvents, and bases is summarized in Table 1.

Table 1. Optimization studies for the reaction of **3** with 4-methoxyphenol **6a** ^a.



Entry ^b	R	Pd Cat	Ligand	Solvent	Base	t (h)	4 (%)	7 (%)
1	Ts	/	/	DMSO	K ₂ CO ₃	0.5	/ (4aa)	/
2	Ts	/	/	MeCN	K ₂ CO ₃	8	/ (4aa)	/
3 ^c	Bz	/	/	DMSO	K ₂ CO ₃	5	/ (4ba)	/
4 ^d	SEM	/	/	DMSO	K ₂ CO ₃	24	23 (4ca)	/
5	SEM	/	/	MeCN	K ₂ CO ₃	24	32 (4ca)	/
6	SEM	[Pd(C ₃ H ₅)Cl] ₂	XPhos	MeCN/THF 4:1	K ₂ CO ₃	2	75 (4ca)	/
7	SEM	Pd ₂ dba ₃	XPhos	MeCN	K ₂ CO ₃	24	37 (4ca)	/
8	SEM	Pd(PPh ₃) ₄	/	MeCN	K ₂ CO ₃	24	38 (4ca)	/
9	SEM	[Pd(C ₃ H ₅)Cl] ₂	XPhos	MeCN/THF 4:1	Cs ₂ CO ₃	17	52 (4ca)	18 (7ca)
10	SEM	[Pd(C ₃ H ₅)Cl] ₂	XPhos	MeCN/THF 4:1	Na ₂ CO ₃	23	62 (4ca)	6 (7ca)
11	SEM	[Pd(C ₃ H ₅)Cl] ₂	XPhos	MeCN/THF 4:1	K ₃ PO ₄	23	49 (4ca)	13 (7ca)
12 ^e	SEM	[Pd(C ₃ H ₅)Cl] ₂	XPhos	MeCN/THF 4:1	^t BuONa	0.5	9 (4ca)	/
13 ^f	SEM	[Pd(C ₃ H ₅)Cl] ₂	XPhos	MeCN/THF 4:1	K ₂ CO ₃	2	65 (4ca)	/
14	SEM	[Pd(C ₃ H ₅)Cl] ₂	RuPhos	MeCN/THF 4:1	K ₂ CO ₃	25	45 (4ca)	21 (7ca)
15	SEM	[Pd(C ₃ H ₅)Cl] ₂	SPhos	MeCN/THF 4:1	K ₂ CO ₃	24	31 (4ca)	20 (7ca)
16	SEM	[Pd(C ₃ H ₅)Cl] ₂	^t BuXPhos	MeCN/THF 4:1	K ₂ CO ₃	4.5	64 (4ca)	2 (7ca)
17	SEM	[Pd(C ₃ H ₅)Cl] ₂	JohnPhos	MeCN/THF 4:1	K ₂ CO ₃	7.5	39 (4ca)	24 (7ca)
18	SEM	[Pd(C ₃ H ₅)Cl] ₂	DavePhos	MeCN/THF 4:1	K ₂ CO ₃	23	47 (4ca)	13 (7ca)
19	SEM	[Pd(C ₃ H ₅)Cl] ₂	XPhos	DMF/THF 4:1	K ₂ CO ₃	24	30 (4ca)	18 (7ca)
20 ^g	SEM	[Pd(C ₃ H ₅)Cl] ₂	XPhos	DMSO/THF 4:1	K ₂ CO ₃	24	20 (4ca)	3 (7ca)
21	Ts	[Pd(C ₃ H ₅)Cl] ₂	XPhos	MeCN/THF 4:1	K ₂ CO ₃	2	97 (4aa)	/
22	Bz	[Pd(C ₃ H ₅)Cl] ₂	XPhos	MeCN/THF 4:1	K ₂ CO ₃	3	57 (4ba)	13 (7ba)

^a Unless otherwise stated, reactions were carried out on a 0.291 mmol scale under an argon atmosphere using 0.05 equiv. of Pd, 0.05 equiv. of ligand, 2 equiv. of **6a**, and 2 equiv. of base in 2.5 mL of anhydrous solvent. ^b Yields are given for isolated products. ^c 3-formyl-*N*-benzylindole was isolated in 35% yield. ^d 3-formyl-*N*-SEMindole was isolated in 53% yield. ^e *N*-SEM-3-carbinol was isolated in 55%. ^f Reaction was carried out with potassium salt of **6a**. ^g 3-formyl-*N*-SEMindole was isolated in 55% yield.


Based on our previous results in analogs of gramine synthesis [18], we started our investigation by reacting the acetates **3a–b** with **6a** in the absence of palladium catalyst. No evidence of the substitution products **4aa** was observed (Table 1, entries 1–3). Slightly better results, but still unsatisfactory from a synthetic point of view, were obtained by switching to (1-SEM-1*H*-indol-3-yl)methyl acetate **3c** (Table 1, entries 4–5). These results suggested that the approach based on the sequential in situ generation under basic condition of indole-based iminium methide (A)/aza-Michael-type addition (Scheme 1) could not be a good strategy for synthesizing the target compounds. We then continued our screening in the presence of palladium catalysis, assuming that the Tsuji–Trost-type reaction could be a suitable protocol for converting **3c** into the corresponding **4ca**.

Taking advantage of our results in palladium-catalyzed benzylic-like nucleophilic substitution of benzofuran-2-ylmethyl acetates with S, O, and C soft nucleophiles [28], we thought that the neutral Pd(allyl)Cl complexes [29,30] containing Buchwald dialkylmonophosphine ligands [31] could be highly effective precatalysts also in the conversion of **3c** to **4ca**. As reported by us, the active palladium Pd(allyl)Cl complex could be generated in situ by dissolving [Pd(η^3 -C₃H₅)Cl]₂ and Buchwald-type ligand in THF at room temperature. Initial attempts were based on the use of [Pd(η^3 -C₃H₅)Cl]₂ as a source of palladium, XPhos as the ligand, MeCN as a solvent in the presence of different bases (Table 1, entries

6, 9–12) at 120 °C. The best results were obtained with K_2CO_3 , having isolated **4ca** in 75% yield (Table 1, entry 6). Substitution of $[Pd(\eta^3-C_3H_5)Cl]_2$ with other sources of palladium [Pd_2dba_3 and $Pd(PPh_3)_4$] and XPhos with other ligands, keeping all other parameters the same, led to worse outcomes (Table 1, entries 7–8, 14–18). A poor yield of **4ca** was obtained by carrying out the reaction in DMF or DMSO instead of MeCN (Table 1, entries 19–20). In approximately all tests starting from **3c**, the C-alkylated compound **7ca** was isolated together with the expected O-alkylated main product **4ca**. Experimental results suggested that the O/C-alkylation ratio, usually affected by the degree of aggregation with bidentate anions, was influenced by several parameters such as the M^+ size, solvation, and nature of the ligand. Eventually, with the optimized reaction conditions in hand ($[Pd(C_3H_5)Cl]_2$, XPhos, MeCN/THF, K_2CO_3 , 120 °C), we compared the reactivity of **3c** with **3b** and **3a**, and we were pleased to find that the desired final product was isolated in 97% yield starting from the *N*-Ts substrate (Table 1, entry 19).

We next explored the scope and generality of the reaction (Table 2).

Table 2. *N*-Ts-1-methyl-3-(aryloxymethyl)-1*H*-indole **4** from *N*-substituted-indol-3-ylmethyl acetates **3** and phenols **6**^a.



Entry ^b	R ¹	3	R ²	6	t (h)	4 (%)
1	H	3a	4- <i>t</i> -Bu	6b	3	83 (4ab)
2	H	3a	4-F	6c	3	81 (4ac)
3	H	3a	2-Ph	6d	1.5	80 (4ad)
4	H	3a	3-CO ₂ Me	6e	3	76 (4ae)
5	H	3a	4-CN	6f	3	46 (4af)
6 ^c	H	3a	4-CN	6f	1	75 (4af)
7	H	3a	4-NO ₂	6g	24	/
8 ^c	H	3a	4-NO ₂	6g	24	/
9	5-OMe	3d	4-OMe	6a	1	90 (4da)
10	5-OMe	3d	4- <i>t</i> -Bu	6b	1.5	94 (4db)
11	5-OMe	3d	2-Ph	6c	1.5	92 (4dd)
12	5-OMe	3d	3-CO ₂ Me	6e	1.5	90 (4de)
13	5-Ph	3e	2-Ph	6d	1	89 (4ed)
14	6-Cl	3f	4- <i>t</i> -Bu	6b	24	/

^a Unless otherwise stated, reactions were carried out on a 0.291 mmol scale under an argon atmosphere at 120 °C using 2.0 equiv. of **6**, 0.025 equiv. of $[Pd(C_3H_5Cl)]_2$ and 0.05 equiv. of XPhos, and 2 equiv. of K_2CO_3 in 2.5 mL of MeCN/THF mixture (4:1). ^b Yields are given for isolated products. ^c Reaction was carried out with potassium salt of **6f** and **6g**.

Good to excellent results were usually obtained with various indoles and phenols. Phenols bearing neutral, electron-releasing, and electron-withdrawing substituents except for the nitro group (Table 2, entries 7 and 8) can be used. Furthermore, the presence of groups close to the C-OH bond does not hamper the reaction (Table 2, entries 3 and 13). Among tested indoles, (6-chloro-1-tosyl-1*H*-indol-3-yl)methyl acetate **3f** leads to a complex reaction mixture, probably for competitive cross-coupling reactions.

The potential of the developed strategy is further highlighted by the investigation of the palladium-catalyzed regioselective sulfonylation of (1-tosyl-1*H*-indol-3-yl)methyl acetates **3** with sulfinic acid salt **8**.

Even if the aryl sulfone fragment is present in several compounds exhibiting important biological activities [32–34], and many protocols have been developed for their synthesis [35–43], less attention has been devoted to the formation of 3-((arylsulfonyl)methyl)-1*H*-indole [44,45]. The sulfonylation of **3a** with commercially available sodium 4-methylbenzenesulfinate **8a** was attempted under the reaction conditions successfully employed with phenols. Lowering the reaction temperature to 100 °C, the indole **9aa** was isolated in 98% yield (Table 3, entry 2). Also with this class of soft nucleophiles, the formation of product **9** by a base-promoted reaction can be ruled out by recovering almost quantitatively the starting indole acetate **3a** under metal-free conditions (Table 3, entry 1). Subsequently, the protocol was extended to include functionalized indoles and arylsulfonates **8** (Table 3).

Table 3. *N*-Ts-1-methyl-3-((arylsulfonyl)methyl)-1*H*-indole **9** from *N*-substituted-indol-3-ylmethyl acetates **3** and sodium arylsulfonates **8** ^a.

Entry ^b	R ¹	3	R ²	8	t (h)	9 (%)
1 ^{c,d}	H	3a	Me	8a	16	/
2	H	3a	Me	8a	1.5	98 (9aa)
3	H	3a	H	8b	1	98 (9ab)
4	5-OMe	3d	Me	8a	1	84 (9da)
5	5-OMe	3d	H	8b	1	76 (9db)
6	5-Ph	3e	Me	8a	1	87 (9ea)
7	5-Ph	3e	H	8b	30	75 (9eb)
8 ^{e,f}	6-Cl	3f	Me	8a	26	75 (9fa)
9 ^g	6-Cl	3f	H	8b	7	62 (9fb)
10	5-NO ₂	3g	H	8a	1	92 (9ga)
11	5-NO ₂	3g	H	8b	6	83 (9gb)

^a Unless otherwise stated, reactions were carried out on a 0.291 mmol scale under an argon atmosphere at 100 °C using 2.0 equiv. of **8**, 0.025 equiv. of [Pd(C₃H₅Cl)₂] and 0.05 equiv. of XPhos, and 2 equiv. of K₂CO₃ in 2.5 mL of MeCN/THF mixture (4:1). ^b Yields are given for isolated products. ^c The reaction was carried out under metal-free conditions. ^d **3a** was isolated in 95% yield. ^e **3f** was isolated in 10% yield. ^f **13a** was isolated in 4% yield. ^g **13b** was isolated in 6% yield.

The formation of the (1-tosyl-1*H*-indol-3-yl)methyl arylsulfinate **10** resulting from the competitive O-attack of the ambident sulfinate anion as well as the desulfination product **11** (Figure 3) was never observed [46–50]. Interestingly, good yields were also obtained by using the (6-chloro-1-tosyl-1*H*-indol-3-yl)methyl acetate **3f** (Table 3, entries 8 and 9) along with a small amount of homocoupling byproduct **13** (Figure 4). Furthermore, the presence of nitro and methoxy on the indole nucleus as substituents was well tolerated (Table 3, entries 4, 5, 10, 11).




Figure 3. Structures of expected byproducts **10** and **11**.





Figure 4. Structures of homocoupling byproducts **13a** and **13b**.

3. Discussion

The regioselective outcome of the functionalization of the 1-substituted-indol-3-yl)methyl acetates **3** with S and O soft nucleophiles represents the principal goal of our investigation. It is known that this type of substrate could generate the (η^3 -indolylmethyl)palladium complex **B** which undergoes the nucleophilic attack of the added nucleophile at the benzylic carbon $C_{1'}$ or C_2 position of the indole ring (Scheme 4).



Scheme 4. Formation of the (η^3 -indolylmethyl)palladium complex **B** and its reaction with nucleophiles.

In all the tested cases, under our reaction conditions, regardless of the nature of the nucleophiles, the reaction led only to the formation of the $C_{1'}$ substituted products in high overall yield.

4. Conclusions

In conclusion, I3C represents a readily available building block for synthesizing highly desirable biologically active indole-containing sulfone and aryloxy fragments. The procedure is of wide scope, tolerates a variety of functional groups, and proceeds in yields ranging from good to excellent in a regioselective manner.

In addition, given the highlighted efficiency and atom economy, the proposed method may represent a reasonable valorization route for the exploitation of I3C and/or its derivative obtained from renewable sources.

5. Materials and Methods

5.1. General Information

All of the commercially available reagents, catalysts, bases, and solvents were used as purchased, without further purification. Starting materials and reaction products were purified by flash chromatography using SiO₂ as stationary phase, eluting with *n*-hexane/ethyl acetate (EtOAc) mixtures. ¹H NMR (400.13 MHz), ¹³C NMR (100.6 MHz), and ¹⁹F spectra (376.5 MHz) were recorded with a Bruker Avance 400 spectrometer. Splitting patterns were designed as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), or bs (broad singlet). HRMS of samples were recorded using a MALDI-TOF spectrometer AB SCIEX TOF/TOF 5800 using matrix in combination with KI for the ionization, with an Orbitrap Exactive (Thermo Fisher, Norristown, PA, USA) mass spectrometer with ESI source positive as well negative. Melting points were determined with a Büchi B-545 apparatus and are uncorrected.

5.2. General Experimental Procedures

Starting materials **3a–c** were prepared according to the literature procedures [18–20,22], through the four-step sequence of reactions depicted in Scheme 2. Starting materials **3d, f, g** were obtained from the corresponding commercially available 3-formylindole. Experimental procedures for **3e** are detailed in Supplementary Materials.

5.2.1. Typical Procedure for the Preparation of 1-Substituted 3-(aryloxymethyl)-1*H*-indole 4: 3-((4-methoxyphenoxy)methyl)-1-tosyl-1*H*-indole **4aa**

In a 50 mL Carousel Tube Reactor (Radely Discovery Technology) containing a magnetic stirring bar, [Pd(η^3 -C₃H₅)Cl]₂ (2.6 mg, 0.007 mmol, 0.025 equiv.) and XPhos (6.7 mg, 0.014 mmol, 0.05 equiv.) were dissolved at room temperature with 0.5 mL of anhydrous THF under argon. Then, (1-tosyl-1*H*-indol-3-yl)methyl acetate **3a** (100.0 mg, 0.290 mmol, 1.00 equiv.), 4-methoxyphenol **6a** (71.9 mg, 0.580 mmol, 2.00 equiv.), K₂CO₃ (80.3 mg, 0.580 mmol, 2.00 equiv.), and 2.0 mL of anhydrous MeCN were added, and the resulting mixture was stirred for 1.5 h at 120 °C under argon. After this time, the reaction mixture was cooled to room temperature, diluted with Et₂O, extracted twice with NaOH 2.0 N, and then washed with brine. The organic layer was dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by chromatography on SiO₂ (25–40 μ m), eluting with 80/20 (*v/v*) *n*-hexane/AcOEt mixture (R_f = 0.24) to obtain 3-((4-methoxyphenoxy)methyl)-1-tosyl-1*H*-indole **4aa** (97% yield, 114.5 mg).

3-((4-methoxyphenoxy)methyl)-1-tosyl-1*H*-indole **4aa**: 97% yield; yellow solid; mp: 132–133 °C; R_f = 0.19 (*n*-hexane/AcOEt, 90:10); IR (neat): 2919, 1694, 1447, 1357, 1176 cm⁻¹; ¹H NMR (400.13 MHz) (CDCl₃): δ 7.95 (d, *J* = 8.3 Hz, 1H), 7.70 (d, *J* = 8.3 Hz, 2H), 7.58 (s, 1H), 7.57 (d, *J* = 7.6 Hz, 1H), 7.31 (td, *J*₁ = 7.8 Hz, *J*₂ = 0.8 Hz, 1H), 7.23 (td, *J*₁ = 7.8 Hz, *J*₂ = 0.6 Hz, 1H), 7.17 (d, *J* = 8.2 Hz, 2H), 6.88 (d, *J* = 9.1 Hz, 2H), 6.80 (d, *J* = 9.1 Hz, 2H), 5.10 (s, 2H), 3.75 (s, 3H), 2.31 (s, 3H); ¹³C NMR (100.6 MHz) (CDCl₃): δ 154.3 (C), 152.7 (C), 145.1 (C), 135.4 (C), 135.2 (C), 130.0 (CH), 129.7 (C), 127.0 (CH), 125.1 (CH), 125.0 (CH), 123.5 (CH), 120.1 (CH), 118.7 (C), 116.2 (CH), 114.8 (CH), 113.8 (CH), 63.3 (CH₂), 55.8 (CH₃), 27.7 (CH₃); HRMS: *m/z* (MALDI-TOF) positive ion, calculated for C₂₃H₂₁KNO₄S: [M+K]⁺ 446.0828, found: 446.0833.

5.2.2. Typical Procedure for the Preparation of 1-tosyl 3-((arylsulfonyl)methyl)-1-tosyl-1*H*-indole 9: Synthesis of 1-tosyl-3-(tosylmethyl)-1*H*-indole **9aa**

In a 50 mL Carousel Tube Reactor (Radely Discovery Technology) containing a magnetic stirring bar, [Pd(η^3 -C₃H₅)Cl]₂ (2.6 mg, 0.007 mmol, 0.025 equiv.) and XPhos (6.7 mg, 0.014 mmol, 0.05 equiv.) were dissolved at room temperature with 0.5 mL of anhydrous THF under argon. Then, (1-tosyl-1*H*-indol-3-yl)methyl acetate **3a** (100.0 mg, 0.290 mmol, 1.00 equiv.), sodium 4-tolylsulfinate **8a** (103.3 mg, 0.580 mmol, 2.00 equiv.), K₂CO₃ (80.3 mg, 0.580 mmol, 2.00 equiv.), and 2.0 mL of anhydrous MeCN were added, and the mixture was stirred for 1.5 h at 100 °C. After this time, the reaction mixture was cooled to room

temperature, diluted with Et₂O, and washed with brine. The organic layer was dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by chromatography on SiO₂ (25–40 μm), eluting with 80/20 (*v/v*) *n*-hexane/AcOEt mixture (*R_f* = 0.24) to obtain 1-tosyl-3-(tosylmethyl)-1*H*-indole **9aa**.

1-tosyl-3-(tosylmethyl)-1*H*-indole **9aa**: 98% yield; red solid; mp: 207–208 °C; *R_f* = 0.24 (*n*-hexane/AcOEt, 80:20); IR (neat): 2927, 1598, 1309, 1163, 659 cm⁻¹; ¹H NMR (400.13 MHz) (CDCl₃): δ 7.95 (d, *J* = 8.2 Hz, 1H), 7.75 (d, *J* = 8.4 Hz, 2H), 7.46 (d, *J* = 8.2 Hz, 2H), 7.39 (s, 1H), 7.32 (d, *J* = 7.7 Hz, 2H), 7.29–7.26 (m, 2H), 7.19–7.15 (m, 1H), 7.13 (d, *J* = 8.2 Hz, 2H), 4.43 (s, 2H), 2.40 (s, 3H), 2.39 (s, 3H); ¹³C NMR (100.6 MHz) (CDCl₃): δ 145.3 (C), 144.9 (C), 135.0 (C), 134.7 (C), 130.0 (overlapping) (CH), 129.7 (C), 129.6 (CH), 128.5 (CH), 127.3 (CH), 126.9 (CH), 125.1 (CH), 123.5 (CH), 119.6 (CH), 113.5 (CH), 110.1 (C), 53.6 (CH₂), 21.6 (overlapping) (CH₃); HRMS: *m/z* (MALDI-TOF) positive ion, calculated for C₂₃H₂₁KNO₄S₂: [M+K]⁺ 478.0549, found: 478.0554.

5.3. Characterization Data of Synthesized Compounds

Characterization data of starting materials **3a–g** are reported in Supplementary Materials.

Characterization Data of Final Compounds **4aa–ed** and **9aa–gb**

1-benzyl-3-((4-methoxyphenoxy)methyl)-1*H*-indole **4ba**: 57% yield; yellow oil; *R_f* = 0.19 (*n*-hexane/AcOEt, 90:10); IR (neat): 2879, 1678, 1435, 1267, 1098, 895 cm⁻¹; ¹H NMR (400.13 MHz) (CDCl₃): δ 7.62 (d, *J* = 7.7 Hz, 1H), 7.20–6.98 (m, 10H), 6.86 (d, *J* = 9.2 Hz, 2H), 6.75 (d, *J* = 9.2 Hz, 2H), 6.80 (d, *J* = 9.1 Hz, 2H), 5.16 (s, 2H), 5.09 (s, 2H), 3.66 (s, 3H); ¹³C NMR (100.6 MHz) (CDCl₃): δ 154.0 (C), 153.3 (C), 137.3 (C), 137.0 (C), 128.9 (CH), 128.0 (CH), 127.7 (CH), 127.0 (CH), 122.3 (CH), 119.9 (CH), 119.5 (CH), 116.2 (CH), 114.7 (CH), 114.7 (CH), 110.0 (CH), 63.3 (CH₂), 55.8 (CH₃), 50.1 (CH₃); HRMS: *m/z* (MALDI-TOF) positive ion, calculated for C₂₃H₂₁NNaO₂: [M+Na]⁺ 366.1470, found: 366.1472.

2-((1-benzyl-1*H*-indol-3-yl)methyl)-4-methoxyphenol **7ba**: 13% yield; brown oil; *R_f* = 0.19 (*n*-hexane/AcOEt, 90:10); IR (neat): 2919, 1596, 1347, 1256, 1177, 989 cm⁻¹; ¹H NMR (400.13 MHz) (CDCl₃): δ 7.49 (d, *J* = 8.2 Hz, 1H), 7.23–7.17 (m, 4H), 7.10 (td, *J*₁ = 7.5 Hz, *J*₂ = 0.8 Hz, 1H), 7.03–7.00 (m, 3H), 6.84 (s, 2H), 6.75 (d, *J* = 2.9 Hz, 1H), 6.80 (d, *J* = 8.7 Hz, 1H), 6.62 (dd, *J*₁ = 8.7 Hz, *J*₂ = 2.9 Hz, 1H), 5.16 (s, 2H), 5.18 (s, 2H), 4.64 (bs, 1H), 4.02 (s, 2H), 3.67 (s, 3H); ¹³C NMR (100.6 MHz) (CDCl₃): δ 153.8 (C), 148.4 (C), 137.6 (C), 137.2 (C), 128.9 (CH), 128.0 (CH), 127.7 (CH), 127.6 (C), 126.8 (C), 126.6 (CH), 122.4 (CH), 119.54 (CH), 119.49 (CH), 116.8 (CH), 116.3 (CH), 112.6 (CH), 112.5 (C), 110.0 (CH), 55.8 (CH₃), 50.1 (CH₂), 27.4 (CH₂); HRMS: *m/z* (MALDI-TOF) positive ion, calculated for C₂₃H₂₁NNaO₂: [M+Na]⁺ 366.1470, found: 366.1473.

3-((4-methoxyphenoxy)methyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1*H*-indole **4ca**: 97% yield; yellow solid; mp: 111–113 °C; *R_f* = 0.23 (*n*-hexane/AcOEt, 80:20); IR (neat): 3030, 2789, 1447, 1327, 1145 cm⁻¹; ¹H NMR (400.13 MHz) (CDCl₃): δ 7.75 (d, *J* = 7.9 Hz, 1H), 7.70 (d, *J* = 8.0 Hz, 1H), 7.31 (td, *J*₁ = 7.0 Hz, *J*₂ = 0.9 Hz, 1H), 7.28–7.21 (m, 2H), 7.03–6.99 (m, 2H), 6.91–6.87 (m, 2H), 5.49 (s, 2H), 5.24 (s, 2H), 3.81 (m, 3H), 3.52 (t, *J* = 8.1 Hz, 2H), 0.93 (t, *J* = 8.1 Hz, 1H), 0.00 (s, 9H); ¹³C NMR (100.6 MHz) (CDCl₃): δ 154.0 (C), 153.3 (C), 137.0 (C), 128.0 (C), 127.5 (CH), 122.7 (CH), 120.5 (CH), 119.5 (CH), 116.1 (CH), 114.7 (CH), 112.2 (C), 110.2 (CH), 75.7 (CH₂), 66.0 (CH₂), 63.3 (CH₂), 55.8 (CH₃), 17.8 (CH₂), -1.33 (CH₃); HRMS: *m/z* (MALDI-TOF) positive ion, calculated for C₂₂H₂₉KNO₃Si: [M+K]⁺ 422.1554, found: 422.1554.

4-methoxy-2-((1-((2-(trimethylsilyl)ethoxy)methyl)-1*H*-indol-3-yl)methyl)phenol **7ca**: 97% yield; yellow oil; *R_f* = 0.21 (*n*-hexane/AcOEt, 80:20); IR (neat): 2988, 1567, 1347, 1278, 1165, 982 cm⁻¹; ¹H NMR (400.13 MHz) (CDCl₃): δ 7.57 (d, *J* = 8.0 Hz, 1H), 7.48 (d, *J* = 8.0 Hz, 1H), 7.25 (dd, *J*₁ = 8.1 Hz, *J*₂ = 0.9 Hz, 1H), 7.15 (dd, *J*₁ = 7.5 Hz, *J*₂ = 0.7 Hz, 1H), 6.99 (s, 1H), 6.82 (d, *J* = 2.9 Hz, 1H), 6.78 (d, *J* = 8.7 Hz, 1H), 6.72 (dd, *J*₁ = 8.7 Hz, *J*₂ = 2.9 Hz, 1H), 5.43 (s, 2H), 4.65 (bs, 1H), 4.09 (s, 2H), 3.76 (m, 3H), 3.45 (t, *J* = 8.1 Hz, 2H), 0.88 (t, *J* = 8.1 Hz, 1H), 0.00 (s, 9H); ¹³C NMR (100.6 MHz) (CDCl₃): δ 148.0 (C), 137.2 (C), 128.4 (C), 127.8 (CH), 126.3 (CH), 122.7 (CH), 120.5 (C), 120.1 (CH), 119.4 (CH), 116.7 (CH), 116.4 (CH), 113.6

(C), 112.6 (CH), 110 (CH), 75.4 (CH₂), 66.0 (CH₂), 63.3 (CH₂), 55.8 (CH₃), 26.9 (CH) 17.8 (CH₂), -1.39 (CH₃); HRMS: *m/z* (MALDI-TOF) positive ion, calculated for C₂₂H₂₉KNO₃Si: [M+K]⁺ 422.1554, found: 422.1554.

3-((4-*tert*-butylphenoxy)methyl)-1-tosyl-1H-indole **4ab**: 83% yield; yellow solid; mp: 126–128 °C; R_f = 0.19 (*n*-hexane/AcOEt, 90:10); IR (neat): 2957, 1596, 1361, 1215, 1100 cm⁻¹; ¹H NMR (400.13 MHz) (CDCl₃): δ 7.98 (d, *J* = 8.2 Hz, 1H), 7.75 (d, *J* = 8.3 Hz, 2H), 7.62 (s, 1H), 7.59 (d, *J* = 7.8 Hz, 1H), 7.36–7.28 (m, 3H), 7.27–7.24 (m, 1H), 7.23–7.18 (m, 2H), 6.92 (d, *J* = 8.8 Hz, 2H), 5.15 (s, 2H), 2.33 (s, 3H), 1.31 (s, 9H); ¹³C NMR (100.6 MHz) (CDCl₃): δ 154.3 (C), 152.7 (C), 145.1 (C), 135.4 (C), 135.2 (C), 130.0 (CH), 129.7 (C), 127.0 (CH), 125.1 (CH), 125.0 (CH), 123.5 (CH), 120.1 (CH), 118.7 (C), 116.2 (CH), 114.8 (CH), 113.8 (CH), 63.3 (CH₂), 55.8 (CH₃), 27.7 (CH₃); HRMS: *m/z* (MALDI-TOF) positive ion, calculated for C₂₆H₂₇KNO₃S: [M+K]⁺ 472.1349, found: 472.1349.

3-((4-fluorophenoxy)methyl)-1-tosyl-1H-indole **4ac**: 81% yield; white solid; mp: 126–127 °C; R_f = 0.19 (*n*-hexane/AcOEt, 90:10); IR (neat): 2957, 1596, 1474, 1366, 1172 cm⁻¹; ¹H NMR (400.13 MHz) (CDCl₃): δ 7.98 (d, *J* = 8.3 Hz, 1H), 7.73 (d, *J* = 8.3 Hz, 2H), 7.60 (s, 1H), 7.59 (d, *J* = 7.4 Hz, 1H), 7.34 (td, *J*₁ = 7.7 Hz, *J*₂ = 0.9 Hz, 1H), 7.25 (td, *J*₁ = 8.4 Hz, *J*₂ = 0.8 Hz, 1H), 7.20 (d, *J* = 8.1 Hz, 2H), 6.98–6.87 (m, 4H), 5.14 (s, 2H), 2.34 (s, 3H); ¹³C NMR (100.6 MHz) (CDCl₃): δ 157.6 (d, *J*_{CF} = 240.0 Hz, C), 154.60 (d, *J*_{CF} = 2.2 Hz, C), 145.2 (C), 135.4 (C), 135.2 (C), 130.0 (CH), 129.6 (C), 126.9 (CH), 125.1 (d, *J*_{CF} = 20.4 Hz, CH), 123.6 (CH), 120.0 (CH), 118.3 (C), 116.3 (d, *J*_{CF} = 8.0 Hz, CH), 116.1 (CH), 115.9 (CH), 113.9 (CH), 63.2 (CH₂), 21.7 (CH₃); HRMS: *m/z* (MALDI-TOF) positive ion, calculated for C₂₂H₁₉FNO₃S: [M+H]⁺ 396.1070, found: 396.1071.

3-((1,1'-biphenyl)-2-yloxy)methyl)-1-tosyl-1H-indole **4ad**: 80% yield; white solid; mp: 125–127 °C; R_f = 0.22 (*n*-hexane/AcOEt, 90:10); IR (neat): 2957, 1596, 1443, 1281, 1118, 1053, cm⁻¹; ¹H NMR (400.13 MHz) (CDCl₃): δ 7.96 (d, *J* = 8.3 Hz, 1H), 7.67 (d, *J* = 8.2 Hz, 2H), 7.51 (d, *J* = 7.1 Hz, 2H), 7.47 (s, 1H), 7.43–7.27 (m, 7H), 7.20–7.15 (m, 3H), 7.12–7.06 (m, 2H), 5.15 (s, 2H), 2.32 (s, 3H); ¹³C NMR (100.6 MHz) (CDCl₃): δ 155.4 (C), 145.0 (C), 138.5 (C), 135.4 (C), 135.3 (C), 132.0 (C), 131.1 (CH), 130.0 (CH), 129.7 (CH), 129.4 (C), 128.7 (CH), 128.1 (CH), 127.1 (CH), 126.9 (CH), 125.0 (CH), 124.8 (CH), 123.4 (CH), 121.9 (CH), 119.9 (CH), 118.9 (C), 113.9 (CH), 113.8 (CH), 63.5 (CH₂), 21.7 (CH₃); HRMS: *m/z* (MALDI-TOF) positive ion, calculated for C₂₈H₂₃KNO₃S: [M+K]⁺ 492.1036, found: 492.1038.

methyl 3-((1-tosyl-1H-indol-3-yl)methoxy)benzoate **4ae**: 83% yield; pale-yellow solid; mp: 128–130 °C; R_f = 0.19 (*n*-hexane/AcOEt, 90:10); IR (neat): 2957, 1714, 1509, 1367, 1099, 998 cm⁻¹; ¹H NMR (400.13 MHz) (CDCl₃): δ 7.95 (d, *J* = 8.3 Hz, 1H), 7.70 (d, *J* = 8.3 Hz, 2H), 7.58 (s, 1H), 7.57 (d, *J* = 7.6 Hz, 1H), 7.31 (td, *J*₁ = 7.8 Hz, *J*₂ = 0.9 Hz, 1H), 7.23 (td, *J*₁ = 7.8 Hz, *J*₂ = 0.6 Hz, 1H), 7.17 (d, *J* = 8.3 Hz, 2H), 6.88 (d, *J* = 9.1 Hz, 2H), 6.80 (d, *J* = 9.1 Hz, 2H), 5.10 (s, 2H), 3.75 (s, 3H), 2.31 (s, 3H); ¹³C NMR (100.6 MHz) (CDCl₃): δ 154.3 (C), 152.7 (C), 145.1 (C), 135.4 (C), 135.2 (C), 130.0 (CH), 129.7 (C), 127.0 (CH), 125.1 (CH), 125.0 (CH), 123.5 (CH), 120.1 (CH), 118.7 (C), 116.2 (CH), 114.8 (CH), 113.8 (CH), 63.3 (CH₂), 55.8 (CH₃), 27.7 (CH₃); HRMS: *m/z* (MALDI-TOF) positive ion, calculated for C₂₄H₂₁KNO₅S: [M+K]⁺ 474.0778, found: 474.0779.

4-((1-tosyl-1H-indol-3-yl)methoxy)benzotrile **4af**: 75% yield; yellow solid; mp: 142–144 °C; R_f = 0.25 (*n*-hexane/AcOEt, 90:10); IR (neat): 2957, 1509, 1216, 1083, 1032, 971 cm⁻¹; ¹H NMR (400.13 MHz) (CDCl₃): δ 8.01–7.99 (m, 2H), 7.75 (d, *J* = 8.2 Hz, 2H), 7.64 (s, 1H), 7.60–7.56 (m, 3H), 7.30–7.22 (m, 3H), 7.38–7.34 (m, 1H), 7.29–7.25 (m, 1H), 7.22 (d, *J* = 8.2 Hz, 2H), 7.02 (d, *J* = 8.8 Hz, 2H) 5.23 (s, 2H), 2.35 (s, 3H); ¹³C NMR (100.6 MHz) (CDCl₃): δ 161.8 (C), 145.4 (C), 135.4 (C), 135.2 (C), 134.2 (CH), 130.1 (CH), 129.3 (C), 127.0 (CH), 125.4 (CH), 125.2 (CH), 123.7 (CH), 119.9 (CH), 119.2 (C), 117.2 (C), 115.7 (CH), 113.9 (CH), 104.6 (C), 62.8 (CH₂), 21.7 (CH₃); HRMS: *m/z* (MALDI-TOF) positive ion, calculated for C₂₃H₁₉N₂O₃S: [M+H]⁺ 403.1116, found: 403.1119.

5-methoxy-3-((4-methoxyphenoxy)methyl)-1-tosyl-1H-indole **4da**: 83% yield; yellow solid; mp: 108–110 °C; R_f = 0.19 (*n*-hexane/AcOEt, 90:10); IR (neat): 2955, 1596, 1366, 1082, 972 cm⁻¹; ¹H NMR (400.13 MHz) (CDCl₃): δ 7.88 (d, *J* = 9.0 Hz, 1H), 7.70 (d, *J* = 8.3 Hz, 2H), 7.56 (s, 1H), 7.18 (d, *J* = 8.2 Hz, 2H), 7.03 (d, *J* = 2.3 Hz, 1H), 6.95 (dd, *J*₁ = 9.0 Hz, *J*₂ = 2.4 Hz, 1H), 6.91 (d, *J* = 9.0 Hz, 2H), 6.83 (d, *J* = 9.1 Hz, 2H), 5.09 (s, 2H), 3.80 (s, 3H), 3.78 (s, 3H);

^{13}C NMR (100.6 MHz) (CDCl_3): δ 154.3 (C), 152.7 (C), 145.1 (C), 135.4 (C), 135.2 (C), 130.0 (CH), 129.7 (C), 127.0 (CH), 125.1 (CH), 125.0 (CH), 123.5 (CH), 120.1 (CH), 118.7 (C), 116.2 (CH), 114.8 (CH), 113.8 (CH), 63.3 (CH_2), 55.8 (CH_3), 27.7 (CH_3); HRMS: m/z (MALDI-TOF) positive ion, calculated for $\text{C}_{24}\text{H}_{23}\text{KNO}_5\text{S}$: $[\text{M}+\text{K}]^+$ 476.0934, found: 476.0931.

3-((4-(*tert*-butyl)phenoxy)methyl)-5-methoxy-1-tosyl-1H-indole **4db**: 97% yield; orange solid; mp: 122–124 °C; R_f = 0.22 (*n*-hexane/AcOEt, 90:10); IR (neat): 2965, 2865, 1509, 1215, 1032, 973 cm^{-1} ; ^1H NMR (400.13 MHz) (CDCl_3): δ 7.87 (d, J = 9.0 Hz, 1H), 7.73 (d, J = 8.3 Hz, 2H), 7.59 (s, 1H), 7.33 (d, J = 8.8 Hz, 2H), 7.20 (d, J = 8.2 Hz, 2H), 7.02 (d, J = 2.3 Hz, 1H), 7.73 (d, J = 8.3 Hz, 2H), 7.98–6.91 (m, 3H), 5.12 (s, 2H), 3.80 (s, 3H), 2.34 (s, 3H), 1.32 (s, 9H); ^{13}C NMR (100.6 MHz) (CDCl_3): 156.6 (C), 156.4 (C), 145.0 (C), 144.1 (C), 135.3 (C), 130.8 (C), 130.1 (C), 130.0 (CH), 126.9 (CH), 126.4 (CH), 125.7 (CH), 118.7 (C), 114.7 (CH), 114.4 (CH), 114.4 (CH), 102.4 (CH), 62.5 (CH_2), 55.8 (CH_3), 34.2 (C), 31.6 (CH_3), 21.7 (CH_3). HRMS: m/z (MALDI-TOF) positive ion, calculated for $\text{C}_{27}\text{H}_{29}\text{KNO}_4\text{S}$: $[\text{M}+\text{K}]^+$ 502.1454, found: 502.1452.

3-(((1,1'-biphenyl)-2-yloxy)methyl)-5-methoxy-1-tosyl-1H-indole **4dc**: 83% yield; yellow solid; mp: 132–135 °C; R_f = 0.19 (*n*-hexane/AcOEt, 90:10); IR (neat): 2975, 1596, 1475, 1294, 1055, 895 cm^{-1} ; ^1H NMR (400.13 MHz) (CDCl_3): δ 7.83 (d, J = 9.1 Hz, 1H), 7.64 (d, J = 8.3 Hz, 2H), 7.49 (dd, J_1 = 8.3 Hz, J_2 = 1.4 Hz, 2H), 7.43 (s, 1H), 7.38–7.27 (m, 5H), 7.16 (d, J = 8.1 Hz, 2H), 7.08 (dd, J_1 = 7.8 Hz, J_2 = 5.4 Hz, 2H), 6.89 (dd, J_1 = 9.0 Hz, J_2 = 2.4 Hz, 1H), 6.82 (d, J = 2.4 Hz, 1H), 5.12 (s, 2H), 3.68 (s, 3H), 2.32 (s, 3H); ^{13}C NMR (100.6 MHz) (CDCl_3): δ 154.3 (C), 152.7 (C), 145.1 (C), 135.4 (C), 135.2 (C), 130.0 (CH), 129.7 (C), 127.0 (CH), 125.1 (CH), 125.0 (CH), 123.5 (CH), 120.1 (CH), 118.7 (C), 116.2 (CH), 114.8 (CH), 113.8 (CH), 63.3 (CH_2), 55.8 (CH_3), 27.7 (CH_3); HRMS: m/z (MALDI-TOF) positive ion, calculated for $\text{C}_{29}\text{H}_{25}\text{KNO}_4\text{S}$: $[\text{M}+\text{K}]^+$ 522.1141, found: 522.1138.

Methyl 3-((5-methoxy-1-tosyl-1H-indol-3-yl)methoxy)benzoate **4de**: 83% yield; yellow solid; mp: 136–138 °C; R_f = 0.19 (*n*-hexane/AcOEt, 90:10); IR (neat): 2956, 1716, 1595, 1475, 1032, 754 cm^{-1} ; ^1H NMR (400.13 MHz) (CDCl_3): δ 7.80 (d, J = 9.0 Hz, 1H), 7.63 (d, J = 8.3 Hz, 2H), 7.61–7.57 (m, 2H), 7.53 (s, 1H), 7.27 (t, J = 8.1 Hz, 1H), 7.13–7.06 (m, 3H), 6.93 (d, J = 2.4 Hz, 1H), 6.87 (d, J_1 = 9.1 Hz, J_2 = 2.4 Hz, 2H), 5.11 (s, 2H), 3.84 (s, 3H), 3.73 (s, 3H), 2.25 (s, 3H); ^{13}C NMR (100.6 MHz) (CDCl_3): δ 154.3 (C), 152.7 (C), 145.1 (C), 135.4 (C), 135.2 (C), 130.0 (CH), 129.7 (C), 127.0 (CH), 125.1 (CH), 125.0 (CH), 123.5 (CH), 120.1 (CH), 118.7 (C), 116.2 (CH), 114.8 (CH), 113.8 (CH), 63.3 (CH_2), 55.8 (CH_3), 27.7 (CH_3); HRMS: m/z (MALDI-TOF) positive ion, calculated for $\text{C}_{25}\text{H}_{23}\text{KNO}_6\text{S}$: $[\text{M}+\text{K}]^+$ 504.0883, found: 504.0880.

3-(((1,1'-biphenyl)-2-yloxy)methyl)-5-phenyl-1-tosyl-1H-indole **4ed**: 89 yield%; gray solid; mp: 130–132 °C d; yellow solid; mp: 110–112 °C; R_f = 0.22 *n*-hexane/AcOEt 90:10; IR (neat): 2965, 2372, 1594, 1374, 1054, 891 cm^{-1} ; ^1H NMR (400.13 MHz) (CDCl_3): δ 7.99 (d, J = 8.7 Hz, 1H), 7.70 (d, J = 8.1 Hz, 2H), 7.59 (d, J = 0.9 Hz, 1H), 7.53–7.46 (m, 6H), 7.42–7.38 (m, 2H), 7.34–7.20 (m, 6H), 7.17 (d, J = 8.1 Hz, 2H), 7.09–7.04 (m, 2H), 5.18 (s, 2H), 2.31 (s, 3H); ^{13}C NMR (100.6 MHz) (CDCl_3): δ 155.3 (C), 145.1 (C), 141.2 (C), 138.4 (C), 136.9 (C), 135.3 (C), 134.8 (C), 131.9 (C), 131.2 (CH), 130.0 (CH), 129.6 (CH), 128.8 (CH), 128.7 (CH), 128.0 (CH), 127.5 (CH), 127.1 (CH), 127.0 (CH), 126.9 (CH), 125.3 (CH), 124.6 (CH), 121.8 (CH), 119.0 (C), 118.6 (CH), 113.9 (CH), 113.7 (CH), 63.3 (CH_2), 21.7 (CH_3); HRMS: m/z (MALDI-TOF) positive ion, calculated for $\text{C}_{34}\text{H}_{27}\text{KNO}_3\text{S}$: $[\text{M}+\text{K}]^+$ 568.1349, found: 568.1347.

3-((phenylsulfonyl)methyl)-1-tosyl-1H-indole **9ab**: 98% yield; yellow solid; mp: 185–187 °C; R_f = 0.20 (*n*-hexane/AcOEt, 87:13); IR (neat): 3000, 2919, 1653, 1454, 1337, 1008 cm^{-1} ; ^1H NMR (400.13 MHz) ($\text{DMSO}-d_6$): δ 7.85 (d, J = 8.3 Hz, 1H), 7.72–7.66 (m, 5H), 7.55–7.49 (m, 4H), 7.41 (d, J = 8.3 Hz, 2H), 7.31 (t, J = 7.5 Hz, 1H), 7.19 (t, J = 7.5 Hz, 1H), 4.92 (s, 2H), 2.34 (s, 3H); ^{13}C NMR (100.6 MHz) ($\text{DMSO}-d_6$): δ 146.3 (C), 138.3 (C), 134.34 (CH), 134.26 (C), 134.2 (C), 130.8 (CH), 130.1 (C), 129.6 (CH), 128.4 (CH), 128.0 (CH), 127.1 (CH), 125.5 (CH), 123.7 (CH), 121.1 (CH), 113.4 (CH), 111.1 (C), 52.0 (CH_2), 21.5 (CH_3); HRMS: m/z (MALDI-TOF) positive ion, calculated for $\text{C}_{22}\text{H}_{19}\text{KNO}_4\text{S}_2$: $[\text{M}+\text{K}]^+$ 464.0393, found: 464.0389.

5-methoxy-1-tosyl-3-(tosylmethyl)-1H-indole **9da**: 84% yield; brown solid; mp: 159–160 °C; R_f = 0.21 (*n*-hexane/AcOEt, 80:20); IR (neat): 2925, 1597, 1167, 802, 535 cm^{-1} ; ^1H NMR

(400.13 MHz) (CDCl₃): δ 7.73 (d, J = 9.0 Hz, 1H), 7.61 (d, J = 8.2 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 7.25 (s, 1H), 7.16 (d, J = 8.1 Hz, 2H), 7.02 (d, J = 8.1 Hz, 2H), 6.80 (dd, J_1 = 9.0 Hz, J_2 = 2.1 Hz, 1H), 6.56 (d, J = 2.1 Hz, 1H), 4.29 (s, 2H), 3.64 (s, 3H), 2.29 (s, 3H), 2.28 (s, 3H); ¹³C NMR (100.6 MHz) (CDCl₃): δ 156.7 (C), 145.3 (C), 145.0 (C), 134.97 (C), 134.7 (C), 130.8 (C), 130.0 (CH), 129.6 (CH), 129.4 (C), 128.7 (CH), 128.0 (CH), 126.9 (CH), 114.7 (CH), 114.6 (CH), 110.3 (C), 101.5 (CH), 55.6 (CH₃), 53.8 (CH₂), 21.70 (CH₃), 21.69 (CH₃); HRMS: m/z (MALDI-TOF) positive ion, calculated for C₂₄H₂₃KNO₅S₂: [M+K]⁺ 508.0655, found: 508.0652.

5-methoxy-3-((phenylsulfonyl)methyl)-1-tosyl-1H-indole 9db: 76% yield; brown solid; mp: 173–174 °C; R_f = 0.23 (*n*-hexane/AcOEt, 78:22); IR (neat): 2925, 1594, 1167, 812, 593 cm⁻¹; ¹H NMR (400.13 MHz) (DMSO-*d*₆): δ 7.72 (d, J = 9.0 Hz, 1H), 7.69–7.65 (m, 3H), 7.63 (d, J = 7.3 Hz, 2H), 7.49–7.45 (m, 3H), 7.40 (d, J = 8.2 Hz, 2H), 6.97 (d, J = 2.4 Hz, 1H), 6.89 (dd, J_1 = 9.0 Hz, J_2 = 2.4 Hz, 1H), 4.89 (s, 2H), 3.66 (s, 3H), 2.34 (s, 3H); ¹³C NMR (100.6 MHz) (DMSO-*d*₆): δ 156.4 (C), 146.1 (C), 138.4 (C), 134.30 (CH), 134.28 (C), 131.3 (C), 130.7 (CH), 129.5 (CH), 128.8 (C), 128.7 (CH), 128.5 (CH), 127.0 (CH), 114.5 (CH), 114.3 (CH), 111.4 (C), 103.3 (CH), 55.8 (CH₃), 52.0 (CH₂), 21.5 (CH₃); HRMS: m/z (MALDI-TOF) positive ion, calculated for C₂₃H₂₁KNO₅S₂: [M+K]⁺ 494.0498, found: 494.0498.

5-phenyl-1-tosyl-3-(tosylmethyl)-1H-indole 9ea: 80% yield; white solid; mp: 162–164 °C; R_f = 0.22 (*n*-hexane/AcOEt 90:10); IR (neat): 2966, 2371, 2260, 1595, 1372, 1014 cm⁻¹; ¹H NMR (400.13 MHz) (CDCl₃): δ 7.96 (d, J = 8.3 Hz, 1H), 7.67 (d, J = 8.2 Hz, 2H), 7.51 (d, J = 7.5 Hz, 2H), 7.47 (s, 1H), 7.42–7.28 (m, 7H), 7.20–7.15 (m, 3H), 7.12–7.06 (m, 2H), 5.15 (s, 2H), 2.32 (s, 3H); ¹³C NMR (100.6 MHz) (CDCl₃): 155.4 (C), 145.0 (C), 138.5 (C), 135.4 (C), 135.3 (C), 132.0 (C), 131.1 (CH), 130.0 (CH), 129.7 (CH), 129.4 (C), 128.7 (CH), 128.1 (CH), 127.1 (CH), 126.9 (CH), 125.0 (CH), 124.8 (CH), 123.4 (CH), 121.9 (CH), 119.9 (CH), 118.9 (C), 113.9 (CH), 113.8 (CH), 63.5 (CH₂), 21.7 (CH₃); HRMS: m/z (MALDI-TOF) positive ion, calculated for C₂₉H₂₅KNO₄S₂: [M+K]⁺ 554.0862, found: 554.0859.

5-phenyl-3-((phenylsulfonyl)methyl)-1-tosyl-1H-indole 9eb: 97% yield; yellow solid; mp: 158–160 °C; R_f = 0.19 *n*-hexane/AcOEt 90:10); IR (neat): 2967, 1450, 1301, 1171, 1032, 887 cm⁻¹; ¹H NMR (400.13 MHz) (CDCl₃): δ 7.98 (d, J = 8.7 Hz, 1H), 7.76 (d, J = 8.1 Hz, 2H), 7.56 (d, J = 7.7 Hz, 2H), 7.53–7.36 (m, 9H), 7.33 (d, J = 7.1 Hz, 1H), 7.31–7.23 (m, 3H), 4.46 (s, 2H), 2.37 (s, 3H); ¹³C NMR (100.6 MHz) (CDCl₃): δ 145.5 (C), 140.9 (C), 137.7 (C), 137.2 (C), 135.0 (C), 134.1 (C), 134.0 (CH), 130.2 (C), 130.1 (CH), 129.0 (CH), 128.8 (CH), 128.7 (CH), 128.0 (CH), 127.4 (CH), 127.3 (CH), 127.1 (CH), 124.8 (CH), 117.9 (CH), 113.9 (CH), 110.3 (C), 53.6 (CH₂), 21.7 (CH₃); HRMS: m/z (MALDI-TOF) positive ion, calculated for C₂₈H₂₃KNO₄S₂: [M+K]⁺ 540.0706, found: 540.0710

6-chloro-1-tosyl-3-(tosylmethyl)-1H-indole 9fa: 75% yield; white solid; mp: 177–178 °C; R_f = 0.23 (*n*-hexane/AcOEt, 85:15); IR (neat): 2922, 2860, 1591, 1137, 673 cm⁻¹; ¹H NMR (400.13 MHz) (CDCl₃): δ 7.88 (d, J = 1.6 Hz, 1H), 7.65 (d, J = 8.4 Hz, 2H), 7.36 (d, J = 8.2 Hz, 2H), 7.28 (s, 1H), 7.23–7.17 (m, 3H), 7.06 (d, J = 8.4 Hz, 3H), 4.30 (s, 2H), 2.32 (s, 6H); ¹³C NMR (100.6 MHz) (CDCl₃): δ 145.8 (C), 145.2 (C), 135.1 (C), 134.8 (C), 134.7 (C), 131.3 (C), 130.3 (CH), 129.8 (CH), 128.6 (CH), 128.3 (C), 127.9 (CH), 127.0 (CH), 124.4 (CH), 120.7 (CH), 113.8 (CH), 110.0 (C), 53.6 (CH₂), 21.79 (CH₃), 21.77 (CH₃); HRMS: m/z (MALDI-TOF) positive ion, calculated for C₂₃H₂₀ClKNO₄S₂: [M+K]⁺ 512.0159, found: 512.0157.

6-chloro-3-((phenylsulfonyl)methyl)-1-tosyl-1H-indole 9fb: 62% yield; white solid; mp: 210–211 °C; R_f = 0.21 (*n*-hexane/AcOEt, 85:15); IR (neat): 2928, 2794, 1597, 1302, 1173, 668 cm⁻¹; ¹H NMR (400.13 MHz) (DMSO-*d*₆): δ 7.84 (s, 1H), 7.75 (d, J = 8.3 Hz, 2H), 7.69 (t, J = 7.1 Hz, 1H), 7.64 (d, J = 8.0 Hz, 2H), 7.60–7.54 (m, 2H), 7.50 (t, J = 7.5 Hz, 2H), 7.45 (d, J = 8.3 Hz, 2H), 7.27 (d, J = 8.6 Hz, 1H), 4.36 (s, 2H), 2.30 (s, 3H); ¹³C NMR (100.6 MHz) (DMSO-*d*₆): δ 145.8 (C), 137.6 (C), 135.1 (C), 134.9 (C), 134.1 (CH), 131.5 (C), 130.3 (CH), 129.1 (CH), 128.6 (CH), 128.2 (C), 127.9 (CH), 127.1 (CH), 124.5 (CH), 120.6 (CH), 113.9 (CH), 109.9 (C), 53.6 (CH₂), 21.8 (CH₃); HRMS: m/z (MALDI-TOF) positive ion, calculated for C₂₂H₁₈ClKNO₄S₂: [M+K]⁺ 498.0003, found: 497.9998.

5-nitro-1-tosyl-3-(tosylmethyl)-1H-indole 9ga: 92% yield; white solid; mp: 230–231 °C; R_f = 0.23 (*n*-hexane/AcOEt, 70:30); IR (neat): 2912, 1508, 1336, 1122, 532 cm⁻¹; ¹H NMR (400.13 MHz) (DMSO-*d*₆): δ 8.36 (d, J = 1.8 Hz, 1H), 8.18 (dd, J_1 = 9.2 Hz, J_2 = 1.8 Hz,

1H), 8.11 (d, $J = 9.2$ Hz, 1H), 7.84–7.82 (m, 3H), 7.50 (d, $J = 8.2$ Hz, 2H), 7.46 (d, $J = 8.2$ Hz, 2H), 7.27 (d, $J = 8.0$ Hz, 2H), 5.00 (s, 2H), 2.37 (s, 3H), 2.33 (s, 3H); ^{13}C NMR (100.6 MHz) (DMSO- d_6): δ 147.0 (C), 145.1 (C), 144.1 (C), 137.2 (C), 135.4 (C), 133.8 (C), 131.2 (CH), 131.1 (CH), 130.1 (C), 130.0 (CH), 128.6 (CH), 127.3 (CH), 120.5 (CH), 117.6 (CH), 114.3 (CH), 112.3 (C), 51.9 (CH₂), 21.6 (CH₃), 21.4 (CH₃). HRMS: m/z (MALDI-TOF) positive ion, calculated for C₂₃H₂₀KN₂O₆S₂: [M+K]⁺ 523.0400, found: 523.0400.

5-nitro-3-((phenylsulfonyl)methyl)-1-tosyl-1H-indole 9gb: 83% yield; white solid; mp: 229–230 °C; $R_f = 0.20$ (*n*-hexane/AcOEt, 70:30); IR (neat): 3100, 1522, 1345, 1125, 535 cm⁻¹; ^1H NMR (400.13 MHz) (CDCl₃): δ 8.16 (dd, $J_1 = 8.3$ Hz, $J_2 = 2.2$ Hz, 1H), 8.07–8.00 (m, 2H), 7.77 (d, $J = 8.3$ Hz, 2H), 7.68 (s, 1H), 7.63–7.58 (m, 2H), 7.57–7.50 (m, 1H), 7.39–7.28 (m, 4H), 4.45 (s, 2H), 2.40 (s, 3H); ^{13}C NMR (100.6 MHz) (CDCl₃): δ 146.4 (C), 144.4 (C), 137.7 (C), 137.5 (C), 134.4 (CH), 134.3 (CH), 130.5 (CH), 130.4 (CH), 129.7 (C), 129.3 (CH), 128.6 (CH), 127.2 (CH), 120.4 (CH), 116.0 (CH), 114.0 (CH), 110.7 (C), 53.3 (CH₂), 21.8 (CH₃); HRMS: m/z (MALDI-TOF) positive ion, calculated for C₂₂H₁₈KN₂O₆S₂: [M+K]⁺ 509.0243, found: 509.0241.

1,1'-ditosyl-3,3'-bis(tosylmethyl)-1H,1'H-6,6'-biindole 13a: 12% yield; white solid; mp: 228–230 °C; $R_f = 0.23$ (*n*-hexane/AcOEt, 70:30); IR (neat): 2943, 1600, 1283, 1159, 535 cm⁻¹; ^1H NMR (400.13 MHz) (CDCl₃): δ 8.04 (s, 1H), 7.72 (d, 2H, $J = 8.3$ Hz), 7.45 (d, 2H, $J = 8.2$ Hz), 7.42–7.33 (m, 2H), 7.32 (s, 1H), 7.25 (d, $J = 8.2$ Hz, 2H), 7.18 (s, 1H), 7.12 (d, $J = 8.2$ Hz, 2H), 4.38 (s, 2H), 3.64 (s, 3H), 2.35 (s, 3H), 2.31 (s, 3H); ^{13}C NMR (100.6 MHz) (CDCl₃): δ 145.7 (C), 145.1 (C), 138.7 (C), 135.4 (C), 134.9 (C), 134.8 (C), 130.3 (CH), 129.8 (CH), 129.1 (C), 128.7 (CH), 127.8 (CH), 127.2 (CH), 123.5 (CH), 120.2 (CH), 112.6 (CH), 110.0 (C), 53.8 (CH₂), 21.82 (CH₃), 21.79 (CH₃); HRMS: m/z (MALDI-TOF) positive ion, calculated for C₄₆H₄₀KN₂O₈S₄: [M+K]⁺ 915.1305, found: 915.1306.

3,3'-bis((phenylsulfonyl)methyl)-1,1'-ditosyl-1H,1'H-6,6'-biindole 13b: 8% yield; white solid; mp: 230–231 °C; $R_f = 0.23$ (*n*-hexane/AcOEt, 70:30); IR (neat): 2922, 1597, 1294, 1170, 583 cm⁻¹; ^1H NMR (400.13 MHz) (CDCl₃): δ 8.04 (s, 1H), 7.65–7.49 (m, 3H), 7.41–7.28 (m, 5H), 7.26 (d, 2H, $J = 8.2$ Hz), 4.41 (s, 2H), 2.31 (s, 3H); ^{13}C NMR (100.6 MHz) (CDCl₃): δ 145.6 (C), 138.6 (C), 137.6 (C), 135.2 (C), 134.8 (C), 134.0 (CH), 130.2 (CH), 129.1 (CH), 128.9 (C), 128.5 (CH), 127.7 (CH), 127.0 (CH), 123.4 (CH), 119.9 (CH), 112.5 (CH), 109.7 (C), 53.7 (CH₂), 21.7 (CH₃); HRMS: m/z (MALDI-TOF) positive ion, calculated for C₄₄H₃₆KN₂O₈S₄: [M+K]⁺ 887.0992, found: 887.0991.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/molecules29143434/s1>. Reference [51] is cited in Supplementary Materials.

Author Contributions: Conceptualization, G.F. and A.I.; methodology, A.I. and A.G.; formal analysis, G.F. and A.G.; investigation, M.C., F.M., A.S. and R.Z.; writing—original draft preparation, A.I. and A.G.; writing—review and editing, G.F. and A.A.; supervision, A.G. and A.I.; project administration, G.F.; funding acquisition, A.G. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by Sapienza University of Rome under Grant “Progetti Ateneo 2023”.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data contained within the article or Supplementary Materials.

Acknowledgments: We gratefully acknowledge Sapienza University of Rome, Catholic University of Sacred Heart, Rome, University of Teramo, and University of L’Aquila.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Atanasov, A.G.; Zotchev, S.B.; Dirsch, V.M.; Supuran, C.T. Natural products in drug discovery: Advances and opportunities. *Nat. Rev. Drug Discov.* **2021**, *20*, 200–216. [[CrossRef](#)] [[PubMed](#)]
2. Ding, Y.; Xue, X. Medicinal Chemistry Strategies for the Modification of Bioactive Natural Products. *Molecules* **2024**, *29*, 689. [[CrossRef](#)] [[PubMed](#)]
3. Umer, S.M.; Solangi, M.; Khan, K.M.; Saleem, R.S.Z. Indole-Containing Natural Products 2019–2022: Isolations, Reappraisals, Syntheses, and Biological Activities. *Molecules* **2022**, *27*, 7586. [[CrossRef](#)]
4. Weng, J.-R.; Tsai, C.-H.; Kulp, S.K.; Chen, C.-S. Indole-3-carbinol as a chemopreventive and anti-cancer agent. *Cancer Lett.* **2008**, *262*, 153–163. [[CrossRef](#)]
5. Fuentes, F.; Paredes-Gonzalez, X.; Kong, A.-N.T. Dietary Glucosinolates Sulforaphane, Phenethyl Isothiocyanate, Indole-3-Carbinol/3,3'-Diindolylmethane: Antioxidative Stress/Inflammation, Nrf2, Epigenetics/Epigenomics and In Vivo Cancer Chemopreventive Efficacy. *Curr. Pharmacol. Rep.* **2015**, *1*, 179–196. [[CrossRef](#)]
6. Caruso, J.A.; Campana, R.; Wei, C.; Su, C.-H.; Hanks, A.M.; Bornmann, W.G.; Keyomarsi, K. Indole-3-carbinol and its N-alkoxy derivatives preferentially target ER α -positive breast cancer cells. *Cell Cycle* **2014**, *13*, 2587–2599. [[CrossRef](#)] [[PubMed](#)]
7. Cram, E.J.; Liu, B.D.; Bjeldanes, L.F.; Firestone, G.L. Indole-3-carbinol Inhibits CDK6 Expression in Human MCF-7 Breast Cancer Cells by Disrupting Sp1 Transcription Factor Interactions with a Composite Element in the CDK6 Gene Promoter. *J. Biol. Chem.* **2001**, *26*, 22332–22340. [[CrossRef](#)]
8. Moiseeva, E.P.; Heukers, R. Indole-3-carbinol-induced modulation of NF- κ B signalling is breast cancer cell-specific and does not correlate with cell death. *Breast Cancer Res. Treat.* **2008**, *109*, 451–462. [[CrossRef](#)]
9. Wang, X.; Zhang, L.; Dai, Q.; Si, H.; Zhang, L.; Eltom, S.E.; Si, H. Combined Luteolin and Indole-3-Carbinol Synergistically Constrains ER α -Positive Breast Cancer by Dual Inhibiting Estrogen Receptor Alpha and Cyclin-Dependent Kinase 4/6 Pathway in Cultured Cells and Xenograft Mice. *Cancers* **2021**, *13*, 2116. [[CrossRef](#)]
10. Centofanti, F.; Buono, A.; Verboni, M.; Tomino, C.; Lucarini, S.; Duranti, A.; Pandolfi, P.P.; Novelli, G. Synthetic Methodologies and Therapeutic Potential of Indole-3-Carbinol (I3C) and Its Derivatives. *Pharmaceuticals* **2023**, *16*, 240. [[CrossRef](#)]
11. Megna, B.W.; Carney, P.R.; Nukaya, M.; Geiger, P.; Kennedy, G.D. Indole-3-carbinol induces tumor cell death: Function follows form. *J. Surg. Res.* **2016**, *204*, 47–54. [[CrossRef](#)] [[PubMed](#)]
12. Fadlalla, K.; Elgendy, R.; Gilbreath, E.; Pondugula, S.R.; Yehualaeshet, T.; Mansour, M.; Serbessa, T.; Manne, U.; Samuel, T. 3-(2-Bromoethyl)-Indole Inhibits the Growth of Cancer Cells and NF-KB Activation. *Oncol. Rep.* **2015**, *34*, 495–503. [[CrossRef](#)] [[PubMed](#)]
13. Park, M.-K.; Rhee, Y.-H.; Lee, H.-J.; Lee, E.-O.; Kim, K.-H.; Park, M.-J.; Jeon, B.-H.; Shim, B.-S.; Jung, C.-H.; Choi, S.-H.; et al. Antiplatelet and antithrombotic activity of indole-3-carbinol in vitro and in vivo. *Phytother. Res.* **2008**, *22*, 58–64. [[CrossRef](#)]
14. Kim, Y.S.; Milner, J.A. Targets for indole-3-carbinol in cancer prevention. *J. Nutr. Biochem.* **2005**, *16*, 65–73. [[CrossRef](#)] [[PubMed](#)]
15. Mohammadi, S.; Seyedhosseini, F.S.; Behnampour, N.; Yazdani, Y. Indole-3-carbinol induces G1 cell cycle arrest and apoptosis through aryl hydrocarbon receptor in THP-1 monocytic cell line. *J. Recept. Signal Transduct.* **2017**, *37*, 506–514. [[CrossRef](#)]
16. Mohammadi, S.; Memarian, A.; Sedighi, S.; Behnampour, N.; Yazdani, Y. Immunoregulatory effects of indole-3-carbinol on monocyte-derived macrophages in systemic lupus erythematosus: A crucial role for aryl hydrocarbon receptor. *Autoimmunity* **2018**, *51*, 199–209. [[CrossRef](#)] [[PubMed](#)]
17. Weng, J.R.; Omar, H.A.; Kulp, S.K.; Chen, C.S. Pharmacological exploitation of indole-3-carbinol to develop potent antitumor agents. *Mini Rev. Med. Chem.* **2010**, *10*, 398–404. [[CrossRef](#)]
18. Arcadi, A.; Berden, G.; Ciogli, A.; Corinti, D.; Crestoni, M.E.; De Angelis, M.; Fabrizi, G.; Goggiamani, A.; Iazzetti, A.; Marrone, F.; et al. Reactivity of Indolylmethylacetates with N, O, and S Soft Nucleophiles: Evidence of 2-Alkylideneindolenines and 3-Alkylideneindoleninium Generation by ESI-MS and IRMPD Spectroscopy. *Eur. J. Org. Chem.* **2022**, *2022*, e202201166. [[CrossRef](#)]
19. Luparello, C.; Cruciatu, I.; Joerger, A.C.; Ocasio, C.A.; Jones, R.; Tareque, R.K.; Bagley, M.C.; Spencer, J.; Walker, M.; Austin, C.; et al. Genotoxicity and Epigenotoxicity of Carbazole-Derived Molecules on MCF-7 Breast Cancer Cells. *Int. J. Mol. Sci.* **2021**, *22*, 3410. [[CrossRef](#)]
20. Wang, Y.-F.; Wang, C.-J.; Feng, Q.-Z.; Zhai, J.-J.; Qi, S.-S.; Zhong, A.-G.; Chu, M.-M.; Xu, D.-Q. Copper-catalyzed asymmetric 1, 6-conjugate addition of in situ generated para-quinone methides with β -ketoesters. *Chem. Commun.* **2022**, *58*, 6653–6656. [[CrossRef](#)]
21. Arcadi, A.; Calcaterra, A.; Fabrizi, G.; Fochetti, A.; Goggiamani, A.; Iazzetti, A.; Marrone, F.; Mazzocanti, G.; Serraiocco, A. One-pot synthesis of dihydroquinolones by sequential reactions of o-aminobenzyl alcohol derivatives with Meldrum's acids. *Org. Biomol. Chem.* **2022**, *20*, 3160–3173. [[CrossRef](#)] [[PubMed](#)]
22. Primault, G.; Legros, J.-Y.; Fiaud, J.-C. Palladium-catalyzed benzylic-like nucleophilic substitution of benzofuran-, benzothiophene- and indole-based substrates by dimethyl malonate anion. *J. Organomet. Chem.* **2003**, *687*, 353–364. [[CrossRef](#)]
23. Arcadi, A.; Aschi, M.; Chiarini, M.; Fabrizi, G.; Fochetti, A.; Goggiamani, A.; Iavarone, F.; Iazzetti, A.; Serraiocco, A.; Zoppoli, R. Experimental Results and Mechanistic Insights on the Reactions of Indolylmethyl Acetates with Soft Carbon Pronucleophiles. *ACS Omega* **2024**, *9*, 28450–28462. [[CrossRef](#)]
24. Arcadi, A.; Calcaterra, A.; Chiarini, M.; Fabrizi, G.; Fochetti, A.; Goggiamani, A.; Iazzetti, A.; Marrone, F.; Marsicano, V.; Serraiocco, A. Synthesis of Indole/Benzofuran-Containing Diarylmethanes through Palladium-Catalyzed Reaction of Indolylmethyl or Benzofuranylmethyl Acetates with Boronic Acids. *Synthesis* **2021**, *54*, 741–753. [[CrossRef](#)]

25. Tang, Y.; Zhuang, K.; Zhang, X.; Xie, F.; Yang, L.; Lin, B.; Cheng, M.; Li, D.; Liu, Y. Ferric Chloride Catalyzed 1,3-Rearrangement of (Phenoxymethyl)heteroarenes to (Heteroaryl)methylphenols. *Eur. J. Org. Chem.* **2020**, *23*, 3441–3451. [[CrossRef](#)]
26. Frigerio, M.; Santagostino, M.; Sputore, S.; Palmisano, G. Oxidation of Alcohols with o-Iodoxybenzoic Acid in DMSO: A New Insight into an Old Hypervalent Iodine Reagent. *J. Org. Chem.* **1995**, *60*, 7272–7276. [[CrossRef](#)]
27. Yoshimura, A.; Zhdankin, V.V. Advances in Synthetic Applications of Hypervalent Iodine Compounds. *Chem. Rev.* **2016**, *116*, 3328–3435. [[CrossRef](#)] [[PubMed](#)]
28. Arcadi, A.; Fabrizi, G.; Fochetti, A.; Ghirga, F.; Goggiamani, A.; Iazzetti, A.; Marrone, F.; Mazzocanti, G.; Serraiocco, A. Palladium-catalyzed Tsuji–Trost-type reaction of benzofuran-2-ylmethyl acetates with nucleophiles. *RSC Adv.* **2021**, *11*, 909–917. [[CrossRef](#)]
29. DeAngelis, A.J.; Gildner, P.G.; Chow, R.; Colacot, T.J. Generating Active “L-Pd(0)” via Neutral or Cationic π -Allylpalladium Complexes Featuring Biaryl/Bipyrazolylphosphines: Synthetic, Mechanistic, and Structure–Activity Studies in Challenging Cross-Coupling Reactions. *J. Org. Chem.* **2015**, *80*, 6794–6813. [[CrossRef](#)]
30. McGarry, K.R.; McDaniel, M.; Chan, B.C.; O’Connor, A.R.J.P. Synthesis and characterization of (π -allyl) palladium (II) complexes containing dialkylbiaryl phosphine ligands. *Polyhedron* **2016**, *114*, 101–109. [[CrossRef](#)]
31. Surry, D.S.; Buchwald, S.L. Biaryl Phosphane Ligands in Palladium-Catalyzed Amination. *Angew. Chem. Int. Ed.* **2008**, *47*, 6338–6361. [[CrossRef](#)]
32. Meadows, D.C.; Gervay-Hague, J. Vinyl sulfones: Synthetic preparations and medicinal chemistry applications. *Med. Res. Rev.* **2006**, *26*, 793–814. [[CrossRef](#)] [[PubMed](#)]
33. Chen, X.; Hussain, S.; Parveen, S.; Zhang, S.; Yang, Y.; Zhu, C. Sulfonyl group-containing compounds in the design of potential drugs for the treatment of diabetes and its complications. *Curr. Med. Chem.* **2012**, *19*, 3578–3604. [[CrossRef](#)] [[PubMed](#)]
34. Zhao, C.; Rakesh, K.P.; Ravidar, L.; Fang, W.-Y.; Qin, H.-L. Pharmaceutical and medicinal significance of sulfur (SVI)-Containing motifs for drug discovery: A critical review. *Eur. J. Med. Chem.* **2019**, *162*, 679–734. [[CrossRef](#)]
35. Simpkins, N.S. *Sulfones in Organic Synthesis*; Pergamon Press: Oxford, UK, 1993.
36. Le Duc, G.; Bernoud, E.; Prestat, G.; Cacchi, S.; Fabrizi, G.; Iazzetti, A.; Madec, D.; Poli, G. Palladium-Catalyzed Aromatic Sulfonylation: A New Catalytic Domino Process Exploiting in situ Generated Sulfinic Anions. *Synlett* **2011**, *2011*, 2943–2946. [[CrossRef](#)]
37. Shavnya, A.; Hesp, K.D.; Mascitti, V.; Smith, A.C. Palladium-Catalyzed Synthesis of (Hetero)Aryl Alkyl Sulfones from (Hetero)Aryl Boronic Acids, Unactivated Alkyl Halides, and Potassium Metabisulfite. *Angew. Chem. Int. Ed.* **2015**, *54*, 13571–13575. [[CrossRef](#)]
38. Johnson, M.W.; Bagley, S.W.; Mankad, N.P.; Bergman, R.G.; Mascitti, V.; Toste, F.D. Application of Fundamental Organometallic Chemistry to the Development of a Gold-Catalyzed Synthesis of Sulfinic Derivatives. *Angew. Chem. Int. Ed.* **2014**, *53*, 4404–4407. [[CrossRef](#)] [[PubMed](#)]
39. Yadav, D.; Menon, R.S. Recent developments in the chemistry of allenyl sulfones. *Org. Biomol. Chem.* **2020**, *8*, 365–378. [[CrossRef](#)] [[PubMed](#)]
40. Liu, J.; Zheng, L. Recent Advances in Transition-Metal-Mediated Chelation-Assisted Sulfonylation of Unactivated C–H Bonds. *Adv. Synth. Catal.* **2019**, *361*, 1710–1732. [[CrossRef](#)]
41. Zhu, J.; Yang, W.-C.; Wang, X.-d.; Wu, L. Photoredox Catalysis in C–S Bond Construction: Recent Progress in Photo-Catalyzed Formation of Sulfones and Sulfoxides. *Adv. Synth. Catal.* **2018**, *360*, 386–400. [[CrossRef](#)]
42. Higham, J.I.; Bull, J.A. Copper catalysed oxidative α -sulfonylation of branched aldehydes using the acid enhanced reactivity of manganese (IV) oxide. *Chem. Commun.* **2020**, *56*, 4587–4590. [[CrossRef](#)] [[PubMed](#)]
43. Gong, B.; Zhu, H.; Liu, Y.; Li, Q.; Yang, L.; Wu, G.; Fan, Q.; Xie, Z.; Le, Z. Palladium-catalyzed sulfonylative coupling of benzyl(allyl) carbonates with arylsulfonyl hydrazides. *Green Synth. Catal.* **2022**, *3*, 110–115. [[CrossRef](#)]
44. Wu, Y.; Chen, J.; Li, L.; Wen, K.; Yao, X.; Pang, J.; Wu, T.; Tang, X. Copper-Mediated Decarboxylative Sulfonylation of Arylacetic Acids with Sodium Sulfinates. *Org. Lett.* **2020**, *22*, 7164–7168. [[CrossRef](#)] [[PubMed](#)]
45. Lu, S.; Zhu, Y.-S.; Yan, K.-X.; Cui, T.-W.; Zhu, X.; Hao, X.-Q.; Song, M.-P. Iron-Catalyzed C–H Sulfonylmethylation of Indoles in Water-PEG400. *Synlett* **2019**, *30*, 1924–1928. [[CrossRef](#)]
46. Cacchi, S.; Fabrizi, G.; Goggiamani, A.; Parisi, L.M.; Bernini, R. Unsymmetrical Diaryl Sulfones and Aryl Vinyl Sulfones through Palladium-Catalyzed Coupling of Aryl and Vinyl Halides or Triflates with Sulfinic Acid Salts. *J. Org. Chem.* **2004**, *69*, 5608–5614. [[CrossRef](#)] [[PubMed](#)]
47. Modha, S.G.; Mehta, V.P.; Van der Eycken, E.V. Transition metal-catalyzed C–C bond formation via C–S bond cleavage: An overview. *Chem. Soc. Rev.* **2013**, *42*, 5042–5055. [[CrossRef](#)] [[PubMed](#)]
48. Ortgies, D.H.; Hassanpour, A.; Chen, F.; Woo, S.; Forgione, P. Desulfination as an Emerging Strategy in Palladium-Catalyzed C–C Coupling Reactions. *Eur. J. Org. Chem.* **2016**, *2016*, 408–425. [[CrossRef](#)]
49. Zhou, X.; Luo, J.; Liu, J.; Peng, S.; Deng, G.-J. Pd-Catalyzed Desulfinitative Heck Coupling with Dioxxygen as the Terminal Oxidant. *Org. Lett.* **2011**, *13*, 1432–1435. [[CrossRef](#)] [[PubMed](#)]

50. Liu, B.; Guo, Q.; Cheng, Y.; Lan, J.; You, J. Palladium-Catalyzed Desulfitative C-H Arylation of Heteroarenes with Sodium Sulfinates. *Chem. Eur. J.* **2011**, *48*, 13415–13419. [[CrossRef](#)]
51. Moseley, J.D.; Murray, P.M.; Turp, E.R.; Tyler, S.N.G.; Burn, R.T. A mild robust generic protocol for the Suzuki reaction using an air stable catalyst. *Tetrahedron* **2012**, *68*, 6010–6017. [[CrossRef](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.